Clinical trial · Observational
Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions
Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions: A Pancardinal-4 Prospective Registry
NCT07737171CI-TRIAL-00119828recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Adult patients who undergo EUS-RFA for treatment of pancreatic lesions
- interventionNames
- Device: Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA)
Primary outcomes (1)
- measure
- Number of participants for whom there is technical success of tumor treatment
- timeFrame
- From time of the procedure to about 3 months post procedure
- description
- Technical success of tumor treatment is defined as successful delivery of EUS-guided radiofrequency ablation (RFA) energy to the target pancreatic lesion with: * Accurate placement of the RFA probe within the intended lesion under EUS guidance * Completion of the planned ablation cycles * Immediate post-ablation sonographic evidence of treatment effect (e.g., hyperechoic changes within lesion indicating coagulative necrosis)
Secondary outcomes (3)
- measure
- Number of participants with post-procedure complications observed within 30 days
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of any pancreatic pre-malignant lesion and/or pancreatic malignancy * Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically Exclusion Criteria: * Patients with co-existing malignancies of other organs (or a prior history of such) * Patients unable to provide informed consent * Patients unable to complete follow-up
References
Publications (0)
Data not yet available
No reference posted for this study.